Ancilia Biosciences, Inc.

Other New York, NY

About

Issuer

Entity type
Corporation
Jurisdiction
Delaware
Sector
Other
Headquarters
New York, NY
Street
3960 Broadway, 6th Floor
Zip
10032

Offering

Total offering
$10.1M
Amount sold
$10.1M
First sale
Feb 13, 2026
Min investment
$0
Securities
Equity
Federal exemption
Rule 506(b)
Investors so far
23

How this filing compares

Ranked #153 of 611 Other filings in April 2026 by offering amount.

Median Other filing in April 2026: $4.3M. This offering is 2.3× the median.

Other New York filings this week: 1791 Capital Partners Evergreen Fund, LP, 1791 Capital Partners, LP, 2E Select Credit Onshore Fund, LP, AG Kai Bo Realty, L.P., ALGER DYNAMIC RETURN FUND LLC

Leadership

ALEXANDRA SAKATOS — Executive Officer (also: Director)

RODOLPHE BARRANGOU — Executive Officer (also: Director)

DALE PFOST — Director

VERA SCHROEDER — Director

GURDANE BHUTANI — Director

Filing details

Ancilia Biosciences, Inc. filed a Form D with the SEC on April 6, 2026.

Other newest Other companies

Other newest companies in New York